Exact Sciences Corporation posted solid Q1 2025 earnings with revenues up 11% year-on-year, driven by strong performance in screening and Precision Oncology segments. Despite the sequential revenue decline, the market response was positive due to promising growth projections and the launch of Cologuard Plus, a next-gen colon cancer screening test. Competition and high market cap valuation pose ...
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. BofA Securities Health Care Conference, Las Vegas Fireside chat on Wednesday, May 14, 2025 at 1:40 p.m. ET (10:40 a.m. PT) The webcas...
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $707 million for the first quarter ended March 31, 2025, compared to $638 million for the same period of 2024. “Our strong first quarter results pave the way for 2025 to mark our most transformative year yet,” sai...
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the company will present 15 abstracts during Digestive Disease Week (DDW) 2025, taking place May 3-6, 2025, in San Diego, California. The abstracts demonstrate high adherence and strong predicted preference for the Cologuard® test along with abstracts...
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch of Oncodetect™—a new test designed to detect molecular residual disease (MRD) across multiple solid tumors. The Oncodetect test provides patients and their healthcare providers with the insights needed to make more informed decisions throug...
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the publication of a comprehensive review in JAMA Oncology that strengthens the evidence supporting the Oncotype DX Breast Recurrence Score test. The peer-reviewed article titled, “Genomic Assays for Breast Cancer in Diverse Populations: Prognostic an...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.